New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:14 EDTCTRXCatamaran long-term growth drivers remain intact, says Leerink
Leerink views 2014 as a transition year for Catamaran (CTRX) with Cigna (CI) and believes the company is well positioned for the 2015 selling season. The firm think Catamaran's long-term growth drivers are still intact despite its weaker than expected 2014 outlook and keeps an Outperform rating on the stock.
News For CTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
07:39 EDTCTRXPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 9, 2014
09:12 EDTCTRXCatamaran acquisition in-line with expectations, says Leerink
Subscribe for More Information
07:37 EDTCTRXCatamaran acquisition likely to be well-received, says Oppenheimer
Subscribe for More Information
October 8, 2014
16:34 EDTCTRXCatamaran to acquire Salveo Specialty Pharmacy for $260M in cash
Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use